

THE APOE4 ALZHEIMER'S ALLIANCE & APOE4.INFO PRESENT

A BETTER TOMORROW THROUGH INNOVATION: NEWAMSTERDAM PHARMA

Welcome to our series exploring potential treatment options for APOE4 carriers, featuring NewAmsterdam Pharma. Join our free virtual webinar to learn about obicetrapib's regulatory pathway to approval and discuss its potential future an Alzheimer's for APOE4 carriers.

Aug 19, 2026
3:00 – 4:00 PM EST
FREE, VIRTUAL, OPEN TO PUBLIC

GUEST SPEAKER



DR. MICHAEL DAVIDSON
CEO, Cardiologist, Lipidologist
NewAmsterdam Pharma

MODERATOR



WILLIAM BURKE
Executive Director
ApoE4 Alzheimer's Alliance

MODERATOR



JULIE GREGORY
Founder, President
ApoE4.Info

NewAmsterdam Pharma is a late-stage, clinical biopharmaceutical company developing lipid-lowering treatments for cardiovascular disease. Their investigational once-daily oral drug Obicetrapib has been shown to significantly reduce plasma levels of p-tau217 (a key Alzheimer's biomarker) in patients with atherosclerotic cardiovascular disease, including ApoE4 carriers, suggesting potential to both lower low-density lipoprotein cholesterol (LDL-C) and impact Alzheimer's disease progression.



**NewAmsterdam
Pharma**

REGISTER NOW: <https://apoe4alzheimersalliance.org/better-tomorrow-1>